Prevention and treatment of indirect drug-induced liver toxicity

Jinsheng GUO

doi:10.3969/j.issn.1001-5256.2022.08.040

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1923-1926

PDF( 1873 KB)

Prevention and treatment of indirect drug-induced liver toxicity

DOI: 10.3969/j.issn.1001-5256.2022.08.040

Jinsheng GUO^{,
,}

Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai Institute of Liver Diseases, Shanghai 200032, China

Research funding:

National Natural Science Foundation of China (91129705);

National Natural Science Foundation of China (81070340);

National Natural Science Foundation of China (30570825)

More Information

Corresponding author: GUO Jinsheng, guo.jinsheng@zs-hospital.sh.cn(ORCID: 0000-0002-9980-8725)
Received Date: 2022-02-21
Accepted Date: 2022-03-22
Published Date: 2022-08-20

Abstract

Abstract

Indirect drug-induced liver toxicity (IDLT) refers to the condition that the use of some therapeutic drugs may induce new liver diseases or exacerbate the original liver disease, with the phenotype of underlying or predisposed liver diseases. IDLT may induce persistent liver injury or even acute liver failure and affect the pharmacotherapy for tumor or other comorbidities, leading to the suspension or termination of ongoing chemotherapy, immunotherapy, and targeted therapy, and therefore, it should be taken seriously in clinical practice. This article elaborates on the mechanisms and prevention strategies of several types of IDLT.
- Chemical and Drug Induced Liver Injury,
- Indirect Drug-Induced Liver Injury,
- Therapeutics

FullText(HTML)

References(22)

References

[1]	HOOFNAGLE JH, EINAR S, BJ RNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. DOI: 10.1056/NEJMra1816149.
[2]	ANDRADE RJ, AITHAL GP, BJÖRNSSON ES, et al. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
[3]	CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259.
[4]	YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. DOI: 10.1007/s12072-017-9793-2.
[5]	LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152: 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
[6]	EKPANYAPONG S, REDDY KR. Hepatitis B virus reactivation: What is the issue, and how should it be managed?[J]. Clin Liver Dis, 2020, 24(3): 317-333. DOI: 10.1016/j.cld.2020.04.002.
[7]	YAO ZH, LIAO WY, HO CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients[J]. Eur J Cancer, 2019, 117: 107-115. DOI: 10.1016/j.ejca.2019.05.032.
[8]	BURNS EA, MUHSEN IN, ANAND K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors[J]. J Immunother, 2021, 44(3): 132-139. DOI: 10.1097/cji.0000000000000358.
[9]	ZHANG X, ZHOU Y, CHEN C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5.
[10]	LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072.
[11]	YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014.
[12]	KOKSAL AS, TOKA B, EMINLER AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma[J]. Ann Oncol, 2017, 28(12): 3103-3104. DOI: 10.1093/annonc/mdx502.
[13]	GODBERT B, PETITPAIN N, LOPEZ A, et al. Hepatitis B reactivation and immune check point inhibitors[J]. Dig Liver Dis, 2021, 53(4): 452-455. DOI: 10.1016/j.dld.2020.08.041.
[14]	PEERAPHATDIT TB, WANG J, ODENWALD MA, et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation[J]. Hepatology, 2020, 72(1): 315-329. DOI: 10.1002/hep.31227.
[15]	JENNINGS JJ, MANDALIYA R, NAKSHABANDI A, et al. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies[J]. Expert Opin Drug Metab Toxicol, 2019, 15(3): 231-244. DOI: 10.1080/17425255.2019.1574744.
[16]	WANG W, LIE P, GUO M, et al. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data[J]. Int J Cancer, 2017, 141(5): 1018-1028. DOI: 10.1002/ijc.30678.
[17]	SUZMAN DL, PELOSOF L, ROSENBERG A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver Int, 2018, 38(6): 976-987. DOI: 10.1111/liv.13746.
[18]	SANJEEVAIAH A, KERR T, BEG MS. Approach and management of checkpoint inhibitor-related immune hepatitis[J]. J Gastrointest Oncol, 2018, 9(1): 220-224. DOI: 10.21037/jgo.2017.08.14.
[19]	GROVER S, RAHMA OE, HASHEMI N, et al. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 13-19. DOI: 10.1200/EDBK_100013.
[20]	ALLARD J, LE GUILLOU D, BEGRICHE K, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease[J]. Adv Pharmacol, 2019, 85: 75-107. DOI: 10.1016/bs.apha.2019.01.003.
[21]	Tamoxifen. LiverTox: Clinical and research information on drug-induced liver injury[M/OL]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
[22]	CATALDI M, CITRO V, RESNATI C, et al. New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: Much more than antioxidants[J]. Adv Ther, 2021, 38(5): 2094-2113. DOI: 10.1007/s12325-021-01669-y.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (375) PDF downloads(67)

Prevention and treatment of indirect drug-induced liver toxicity

DOI: 10.3969/j.issn.1001-5256.2022.08.040

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Prevention and treatment of indirect drug-induced liver toxicity

DOI: 10.3969/j.issn.1001-5256.2022.08.040

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content